Developing new immunogens to stimulate immune responses against HIV
Eliciting neutralizing antibodies and B cell responses using novel HIV Env immunogens in non-human primates
This study is exploring new ways to help the immune system create strong defenses against HIV by testing innovative vaccine designs in monkeys, which could lead to better vaccines for people in the future.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11012892 on NIH RePORTER |
What this research studies
This research focuses on creating novel immunogens that can effectively elicit neutralizing antibodies against HIV-1 in non-human primates. By using advanced techniques such as targeted N-glycan deletions and high-density liposomal arrays, the study aims to enhance B cell responses and improve the efficacy of potential HIV vaccines. The approach includes a prime-boost strategy to activate the immune system more effectively, which could lead to better protection against HIV. The findings from this research could pave the way for developing a successful HIV vaccine.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would be individuals at risk for HIV or those involved in HIV vaccine trials.
Not a fit: Patients who are already living with HIV and are receiving treatment may not directly benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of an effective vaccine that provides long-lasting immunity against HIV.
How similar studies have performed: Previous research has shown promising results in eliciting broadly neutralizing antibodies in animal models, indicating potential for success in this novel approach.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Wyatt, Richard Thomas — Scripps Research Institute, the
- Study coordinator: Wyatt, Richard Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.